NLA101 in Adults Receiving High Dose Chemotherapy for AML
Status:
Terminated
Trial end date:
2019-03-18
Target enrollment:
Participant gender:
Summary
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and
efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects
with AML.